Claris Bio emerged with $118 million in new funding to drive two pivotal trials for its corneal disease eye drop program. The company said it will move to Phase 3 testing for CSB-001, targeting limbal stem cell deficiency, a rare condition with no approved pharmacologic therapy and limited treatment options beyond procedures. The round positions Claris to recruit and execute pivotal studies expected to start in 2027, according to the company’s disclosures. Investors include Novo Holdings, alongside led participation from Samsara Biocapital and Catalio Capital Management. For the sector, the deal underscores ongoing appetite for late-stage-ready therapeutics in ophthalmology—especially when the clinical need is high and the asset has prior signals that can be carried into registrational studies.